The potential cardioprotective effects of amifostine in irradiated rats

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 4, 2004, Pages 1228-1234

  Tokatli, Fusun ^a   Uzal, Cem ^a   Doganay, Latife ^a   Kocak, Zafer ^a   Kaya, Meryem ^a   Ture, Mevlut ^a   Kurum, Turhan ^a   Alkaya, Fadime ^a   Karadag, Hakan ^a   Kutlu, Kemal ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Amifostine; Brain natriuretic peptide; Cardiac toxicity; Myocardial damage; Radiation

Indexed keywords

BRAIN; IRRADIATION; LIVING SYSTEMS STUDIES; TUMORS;

CARDIOPROTECTIVE EFFECTS; PLASMA BRAINS;

CARDIOLOGY;

AMIFOSTINE; BRAIN NATRIURETIC PEPTIDE; COBALT 60; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DEGENERATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; HEART PROTECTION; IRRADIATION; MALE; MYOCARDIAL DISEASE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AMIFOSTINE; ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; COBALT RADIOISOTOPES; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HEART; MALE; NATRIURETIC PEPTIDE, BRAIN; RADIATION DOSAGE; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 12144290580     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.071     Document Type: Article

References (43)

1. Schultz-Hector S., Sund M., Thames H.D. Fractionation response and repair kinetics of radiation-induced heart failure in the rat. Radiother Oncol. 23:1992;33-40.
2. Gustavsson A., Eskilsson J., Landberg T., et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol. 1:1990;355-363.
3. Hancock S.L., Donaldson S.S., Hoppe R.T. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 11:1993;1208-1215.
4. Reinders J.J., Heijmen B.J., Olofsen-van Acht M.J., et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol. 51:1999;35-42.
5. Early Breast Cancer Trialist's. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials. Lancet 2000;355:1757-1770.
6. Lauk S. Endothelial alkaline phosphatase activity loss as an early stage in the development of radiation-induced heart disease in rats. Radiat Res. 110:1987;118-128.
7. Lauk S., Kiszel Z., Buschmann J., Trott K. Radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys. 11:1985;801-808.
8. Stewart J.R., Fajardo L.F., Sharon M.G., Constine L.S. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 31:1995;1205-1211.
9. Kjaer A., Hesse B. Heart failure and neuroendocrine activation Diagnostic, prognostic and therapeutic perspectives. Clin Physiol. 21:(Suppl. 6):2001;661-672.
10. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction (see comments). Lancet. 351:1998;9-13.
11. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 96:1997;509-516.
12. Persons C.C., Franken N.A., Wondergem J. Changes in myocardial and circulating atrial natriuretic peptide following thorax irradiation in rat. Int J Radiat Biol. 70:(Suppl. 1):1996;61-68.
13. Meinardi M.T., van Veldhuisen D.J., Gietema J.A., et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 19:2001;2746-2753.
14. Tikanoja T., Riikonen P., Perkkiö M., Helenius T. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediat Oncol. 31:1998;73-78.
15. Wondergem J., Strootman E.G., Frölich M., et al. Circulating atrial natriuretic peptide levels as a marker for cardiac damage after radiotherapy. Radiother Oncol. 58:(Suppl. 3):2001;295-301.
16. Wondergem J., Persons K., Zurcher C., et al. Changes in circulating atrial natriuretic peptide in relation to the cardiac status of Rhesus monkeys after total-body irradiation. Radiother Oncol. 53:1999;67-75.
17. Spencer C.M., Goa K.L. Amifostine A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs. 50:(Suppl. 6):1995;1001-1031.
18. Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065 in vivo. Eur J Cancer 1996;32A(Suppl. 4):21-25.
19. DeLena M., Catino A., Calabrese P., et al. Amifostine (AMF) protects against doxorubucin (D) toxicity with preservation of therapeutic activity in advanced breast cancer (ABC) patients. (Abstr.) Proc Am Soc Clin Oncol. 17:1998;137a.
20. Nazeyrollas P., Prevost A., Baccard N., et al. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol. 43:(Suppl. 3):1999;227-232.
21. Green D., Wright A., Schein P., et al. WR-2721 chemoprotection of doxorubicin toxicity in mice. [Abstract] Proc Am Assoc Cancer Res. 33:1992;490.
22. Dobric S., Dragojevic-Simic V., Bokonjic D., et al. The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats. J Environ Pathol Toxicol Oncol. 17:1998;291-299.
23. Kruse J.J.C.M., Strootman E.G., Wondergem J. Effects of amifostine on radiation-induced cardiac damage. Acta Oncol. 42:2003;4-9.
24. Nousiainen T., Jantunen E., Vanninen E., et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol. 62:(Suppl. 2):1999;135-141.
25. Wondergem J., Franken N.A., Chin A., et al. Additive effect of concomitant multiple low-dose doxorubicin and thoracic irradiation on ex vivo cardiac performance of the rat heart. J Cancer Res Clin Oncol. 124:(Suppl. 3-4):1998;148-154.
26. Dalloz F., Maignon P., Cottin Y., et al. Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Free Radic Biol Med. 26:(Suppl. 7-8):1999;785-800.
27. Büntzel J., Kuttner K., Frohlich D., Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 9:1998;505-509.
28. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 18:2000;3339-3345.
29. Tannehill S.P., Mehta M.P., Larson M., et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer Results of a phase II trial. J Clin Oncol. 15:1997;2850-2857.
30. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;915-922.
31. Echols F.S., Yuhas J.M. Chemoprotection against fractionated radiation exposures with WR2721 Skin injury. Radiat Res. 66:1976;449.
32. Utley J.F., Phillips T.L., Kane L.J. Protection of normal tissues by WR2721 during fractionated irradiation. Int J Radiat Oncol Biol Phys. 1:1976;699-703.
33. Yuhas J.M. Biological factors affecting the radioprotective effectiveness of S-2-(3-aminopropylamino) ethylphosphorothioic acid WR2721 LD50/30 doses. Radiat Res. 44:1970;621.
34. Dorr R.T., Lagel K.E. Antracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. [Abstract] Proc Am Soc Clin Oncol. 13:1994;435.
35. Schultz-Hector S. Radiation-induced heart disease Review of experimental data on dose response and pathogenesis. Int J Radiat Biol. 61:1992;149-160.
36. Sigdestad C.P., Grdina D.J., Connor A.M., et al. A comparison of radioprotection from three neutron sources and Co60 by WR-2721 and WR-151327. Radiat Res. 106:1986;224-233.
37. Rasey J.S., Nelson N.J., Mahler P., et al. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721 LD50 studies and 35S-WR-2721 biodistribution. Radiat Res. 97:(Suppl. 3):1984;598-607.
38. Hopewell J.W., Trott K.R. Volume effects in radiobiology as applied to radiotherapy. Radiother Oncol. 56:2000;283-288.
39. Cilliers G.D., Harper I.S., Lochner A. Radiation-induced changes in the ultrastructure and mechanical function of the rat heart. Radiother Oncol. 16:(Suppl. 4):1989;311-326.
40. Cilliers G.D., Lochner A. Radiation-induced damage of the Wistar rat heart Biochemistry and function. Radiother Oncol. 27:1993;216-222.
41. Yeung T.K., Lauk S., Simmonds R.H., et al. Morphological and functional changes in the rat heart after X irradiation Strain differences. Radiat Res. 119:(Suppl. 3):1989;489-499.
42. Fajardo L.F., Steward J.R. Experimental radiation-induced heart disease. Am J Pathol. 59:1970;299-315.
43. Strender L.E., Lindahl J., Larsson L.E. Incidence of heart disease and functional significance of changes in the electrocardiogram 10 years after radiotherapy for breast cancer. Cancer. 57:1986;929-934.